Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Hal E Broxmeyer, Christie M Orschell, D Wade Clapp, Giao Hangoc, Scott Cooper, P Artur Plett, W Conrad Liles, Xiaxin Li, Barbara Graham-Evans, Timothy B Campbell, Gary Calandra, Gary Bridger, David C Dale, Edward F Srour, Hal E Broxmeyer, Christie M Orschell, D Wade Clapp, Giao Hangoc, Scott Cooper, P Artur Plett, W Conrad Liles, Xiaxin Li, Barbara Graham-Evans, Timothy B Campbell, Gary Calandra, Gary Bridger, David C Dale, Edward F Srour

Abstract

Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization is clinically important because increased numbers of these cells are needed for enhanced transplantation. Chemokine stromal cell derived factor-1 (also known as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow. AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated in murine and human systems for mobilizing capacity, alone and in combination with granulocyte colony-stimulating factor (G-CSF). AMD3100 induced rapid mobilization of mouse and human HPCs and synergistically augmented G-CSF-induced mobilization of HPCs. AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary and secondary lethally-irradiated mice, and human CD34(+) cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice. AMD3100 synergized with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs). Human CD34(+) cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that was characteristic of highly engrafting mouse HSCs. Synergy of AMD3100 and G-CSF in mobilization was due to enhanced numbers and perhaps other characteristics of the mobilized cells. These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization.

Figures

Figure 1.
Figure 1.
Time and dose response effects of AMD3100 as a mobilizer of HPC (CFU-GM, BFU-E and CFU-GEMM) to the blood of mice. (A) Time course of mobilization in response to a single s.c. injection of 5 mg/kg AMD3100 into C3H/HeJ mice; results are for one full experiment (5 mice/group and time 0 control numbers of CFU-GM, BFU-E, and CFU-GEMM per ml of blood were 78 ± 18, 17 ± 2, and 10 ± 2, respectively). (B) Dose response analysis at 1 h post s.c. injections of 0.625, 1.25, 2.5, 5.0, or 10 mg/kg AMD3100 into C3H/HeJ mice; results are average of 7 mice/group from a total of two separate experiments. (C) Influence of multiple injections of 5 mg/kg AMD3100 or saline given on day 1; days 1 and 2; or days 1, 2, and 3 given 24 h apart, and analyzed 1 h after the last injection into C3H/HeJ mice; results are average of 14 mice for control group for different timed saline injections and 8 mice for each test group from a total of two complete experiments. *P

Figure 2.

Comparative AMD3100 enhancement of G-CSF–induced…

Figure 2.

Comparative AMD3100 enhancement of G-CSF–induced mobilization of CFU-GM, BFU-E, and CFU-GEMM in: (A)…

Figure 2.
Comparative AMD3100 enhancement of G-CSF–induced mobilization of CFU-GM, BFU-E, and CFU-GEMM in: (A) 2 d G-CSF: C57Bl/6, C3H/HeJ, DBA/2, (B) 4 d G-CSF: C57Bl/6, and (C) 4 d of G-CSF: Fancc−/− and +/+ mice. The results shown in A are an average from a total of three experiments of 15 C57Bl/6, 15 DBA/2, and 11 C3H/HeJ mice. Results in B are for one experiment of 5 mice/group. Results shown in C are the averages of 15 wild-type and 8 Fancc−/− mice per group averaged from a total of two experiments. For parts A–C, all experimental points within a group are at least P < 0.001 compared with the control for the specific progenitor cell of each mouse strain.

Figure 3.

AMD3100 mobilizes competitive repopulating mouse…

Figure 3.

AMD3100 mobilizes competitive repopulating mouse HSCs with self-renewal capacity (A) and G-CSF synergizes…

Figure 3.
AMD3100 mobilizes competitive repopulating mouse HSCs with self-renewal capacity (A) and G-CSF synergizes this effect (B). (A, left) 18 C57Bl/6 mice (CD45.2) serving as donors were injected s.c. with 0.1 ml saline, and 36 C57Bl/6 mice were injected with 0.1 ml AMD3100 at 5 mg/kg (=∼100 μg/mouse). Blood was collected 1 h later and LDMNCs isolated. BM from nonirradiated B6.BoyJ (CD45.1) mice served as competitor cells. The ratio of donor (CD45.2) blood cells to competitor (CD45.1) BM cells was set as the number of LDMNC blood cells in 3 donor mice to a constant number of 0.5 × 106 competitor BM cells equaling 3:1. A 2:1 ratio was the number of LDMNCs in blood of 2 donor mice to 0.5 × 106 competitor cells, and a 1:1 ratio was LDMNC in 1 donor mouse to 0.5 × 106 competitor cells. Results are based on analysis of transplantation of 6 lethally irradiated recipients per test group of i.v. infused cells. Right panel: BM cells were removed from femurs of primary mice 4 mo after injection of 3:1 saline or 3:1 AMD3100:competitor cell mixture and 2.5 × 106 marrow cells from 3 mice of each group injected separately into 3 lethally secondary irradiated B6.BoyJ mice in a noncompetitive assay. Results are shown as percent CD45.2 C57Bl/6 donor cell chimerism in CD45.1 B6.BoyJ recipients. *P < 0.05; **P < 0.01; ***P < 0.001 compared with group 1 at each time point. (B) G-CSF and AMD3100 were administered as in Figure 2, part A, with G-CSF given twice a day for 2 d. Left panel: competitive repopulation in primary recipients 6 mo post transplant. The results are an average of mouse cells from five donors into six recipients each. Right panel: secondary repopulation in a noncompetitive assay 6 mo after transplant. Results are an average of 3 donor mice with cells transplanted into three recipients each. *P < 0.01 or **P < 0.001 compared with control.

Figure 4.

Influence of AMD3100, alone and…

Figure 4.

Influence of AMD3100, alone and with G-CSF, on circulating HPCs in healthy human…

Figure 4.
Influence of AMD3100, alone and with G-CSF, on circulating HPCs in healthy human volunteers. (A) Influence of multiple injections of AMD3100 alone. Three volunteers were injected i.v. with AMD3100 (80 μg/kg) on the first day (day 1) and again at 24 h. Progenitors/ml blood were assessed preinjection (day 1, 0 h) and at the noted time intervals. Fold changes are calculated based on the following day 1, 0 h progenitors/ml for three donors: CFU-GM (387, 78, 201), BFU-E (712, 78, 217), and CFU-GEMM (77, 29, 93) grown in methylcellulose cultures in the presence of Epo, stem cell factor, and interleukin-3. The fold changes for CFU-GM also include progenitor cells/ml as calculated in agar culture medium with GM-CSF and stem cell factor (control numbers for three donors: 108, 18, 54). *P n = 3), G-CSF + AMD3100 (160 μg/kg; n = 3), or AMD3100 (240 μg/kg; n = 4). *P < 0.01 for G-CSF– or AMD3100 versus G-CSF + AMD3100-mobilized cells. (D) Results of apheresis shown in C but expressed as progenitors mobilized per kg donor. *P < 0.05 for same comparisons as in C.

Figure 5.

Influence of AMD3100, G-CSF, and…

Figure 5.

Influence of AMD3100, G-CSF, and the combination of G-CSF plus AMD3100 on mobilization…

Figure 5.
Influence of AMD3100, G-CSF, and the combination of G-CSF plus AMD3100 on mobilization of NOD-SCID SRCs from normal human volunteers (apheresis samples), surface expression of adhesion molecules and chemotaxis of CD34+ cells, and homing of mobilized murine Sca1+Lin− cells. (A) SRCs per kg in apheresis samples from G-CSF– (n = 3), G-CSF + AMD3100- (160 μg/kg; n = 3), and AMD3100- (240 μg/kg; n = 4) mobilized circulating blood. Each set of test samples was assayed simultaneously in limiting dilutions in conditioned NOD-SCID mice. For every sample, four different cell concentrations were used and four mice were transplanted with each cell concentration. Mice were assayed for chimerism 8 wk later; those that demonstrated >0.2% chimerism (total CD45+ cells in BM) were considered to be positive. Percentage of negative mice were used to calculate SRC frequencies. (B, i) Expression of CD49d (VLA-4), CD49e (VLA-5), CD26L (L-selectin), and CXCR4 on mobilized CD34+ cells (mean ± 1SEM of percent positive cells of five to seven different G-CSF samples, three AMD3100 plus G-CSF samples, and four BM samples). (B, ii) Mean fluorescent intensity (MFI) of positive samples. Same number of samples evaluated as in B, i except G-CSF group has a different number (n =7). (C) CD34+ cells isolated from G-CSF (n = 6) and G-CSF plus AMD3100 (n = 3) mobilized peripheral blood were assessed for chemotaxis to SDF-1/CXCL12 (100 ng/ml) and results expressed as percentage of migrated cells. Data for each sample were collected in duplicate. (D, i) Homing of CD45.2+ Sca1+Lin− BM cells from C57Bl/6 mice into lethally irradiated CD45.1+ B6.BoyJ BM from samples mobilized with G-CSF (2 times/d for 4 d as in Fig. 2B; n = 3), G-CSF + AMD3100 (5 mg/kg; n = 4), and AMD3100 (5 mg/kg; n = 3). Homing was assessed as in Materials and methods. (D, ii) Competitive repopulation of CD45.2+ BM cells recovered after homing shown in D, i. Results of chimerism are after 4 mo in 2° irradiated B6.BoyJ recipients. For A–D, significant differences compared with G-CSF: *P < 0.001; **P < 0.01; ***P < 0.05; all other values are P > 0.05. NA, data not depicted.
Figure 2.
Figure 2.
Comparative AMD3100 enhancement of G-CSF–induced mobilization of CFU-GM, BFU-E, and CFU-GEMM in: (A) 2 d G-CSF: C57Bl/6, C3H/HeJ, DBA/2, (B) 4 d G-CSF: C57Bl/6, and (C) 4 d of G-CSF: Fancc−/− and +/+ mice. The results shown in A are an average from a total of three experiments of 15 C57Bl/6, 15 DBA/2, and 11 C3H/HeJ mice. Results in B are for one experiment of 5 mice/group. Results shown in C are the averages of 15 wild-type and 8 Fancc−/− mice per group averaged from a total of two experiments. For parts A–C, all experimental points within a group are at least P < 0.001 compared with the control for the specific progenitor cell of each mouse strain.
Figure 3.
Figure 3.
AMD3100 mobilizes competitive repopulating mouse HSCs with self-renewal capacity (A) and G-CSF synergizes this effect (B). (A, left) 18 C57Bl/6 mice (CD45.2) serving as donors were injected s.c. with 0.1 ml saline, and 36 C57Bl/6 mice were injected with 0.1 ml AMD3100 at 5 mg/kg (=∼100 μg/mouse). Blood was collected 1 h later and LDMNCs isolated. BM from nonirradiated B6.BoyJ (CD45.1) mice served as competitor cells. The ratio of donor (CD45.2) blood cells to competitor (CD45.1) BM cells was set as the number of LDMNC blood cells in 3 donor mice to a constant number of 0.5 × 106 competitor BM cells equaling 3:1. A 2:1 ratio was the number of LDMNCs in blood of 2 donor mice to 0.5 × 106 competitor cells, and a 1:1 ratio was LDMNC in 1 donor mouse to 0.5 × 106 competitor cells. Results are based on analysis of transplantation of 6 lethally irradiated recipients per test group of i.v. infused cells. Right panel: BM cells were removed from femurs of primary mice 4 mo after injection of 3:1 saline or 3:1 AMD3100:competitor cell mixture and 2.5 × 106 marrow cells from 3 mice of each group injected separately into 3 lethally secondary irradiated B6.BoyJ mice in a noncompetitive assay. Results are shown as percent CD45.2 C57Bl/6 donor cell chimerism in CD45.1 B6.BoyJ recipients. *P < 0.05; **P < 0.01; ***P < 0.001 compared with group 1 at each time point. (B) G-CSF and AMD3100 were administered as in Figure 2, part A, with G-CSF given twice a day for 2 d. Left panel: competitive repopulation in primary recipients 6 mo post transplant. The results are an average of mouse cells from five donors into six recipients each. Right panel: secondary repopulation in a noncompetitive assay 6 mo after transplant. Results are an average of 3 donor mice with cells transplanted into three recipients each. *P < 0.01 or **P < 0.001 compared with control.
Figure 4.
Figure 4.
Influence of AMD3100, alone and with G-CSF, on circulating HPCs in healthy human volunteers. (A) Influence of multiple injections of AMD3100 alone. Three volunteers were injected i.v. with AMD3100 (80 μg/kg) on the first day (day 1) and again at 24 h. Progenitors/ml blood were assessed preinjection (day 1, 0 h) and at the noted time intervals. Fold changes are calculated based on the following day 1, 0 h progenitors/ml for three donors: CFU-GM (387, 78, 201), BFU-E (712, 78, 217), and CFU-GEMM (77, 29, 93) grown in methylcellulose cultures in the presence of Epo, stem cell factor, and interleukin-3. The fold changes for CFU-GM also include progenitor cells/ml as calculated in agar culture medium with GM-CSF and stem cell factor (control numbers for three donors: 108, 18, 54). *P n = 3), G-CSF + AMD3100 (160 μg/kg; n = 3), or AMD3100 (240 μg/kg; n = 4). *P < 0.01 for G-CSF– or AMD3100 versus G-CSF + AMD3100-mobilized cells. (D) Results of apheresis shown in C but expressed as progenitors mobilized per kg donor. *P < 0.05 for same comparisons as in C.
Figure 5.
Figure 5.
Influence of AMD3100, G-CSF, and the combination of G-CSF plus AMD3100 on mobilization of NOD-SCID SRCs from normal human volunteers (apheresis samples), surface expression of adhesion molecules and chemotaxis of CD34+ cells, and homing of mobilized murine Sca1+Lin− cells. (A) SRCs per kg in apheresis samples from G-CSF– (n = 3), G-CSF + AMD3100- (160 μg/kg; n = 3), and AMD3100- (240 μg/kg; n = 4) mobilized circulating blood. Each set of test samples was assayed simultaneously in limiting dilutions in conditioned NOD-SCID mice. For every sample, four different cell concentrations were used and four mice were transplanted with each cell concentration. Mice were assayed for chimerism 8 wk later; those that demonstrated >0.2% chimerism (total CD45+ cells in BM) were considered to be positive. Percentage of negative mice were used to calculate SRC frequencies. (B, i) Expression of CD49d (VLA-4), CD49e (VLA-5), CD26L (L-selectin), and CXCR4 on mobilized CD34+ cells (mean ± 1SEM of percent positive cells of five to seven different G-CSF samples, three AMD3100 plus G-CSF samples, and four BM samples). (B, ii) Mean fluorescent intensity (MFI) of positive samples. Same number of samples evaluated as in B, i except G-CSF group has a different number (n =7). (C) CD34+ cells isolated from G-CSF (n = 6) and G-CSF plus AMD3100 (n = 3) mobilized peripheral blood were assessed for chemotaxis to SDF-1/CXCL12 (100 ng/ml) and results expressed as percentage of migrated cells. Data for each sample were collected in duplicate. (D, i) Homing of CD45.2+ Sca1+Lin− BM cells from C57Bl/6 mice into lethally irradiated CD45.1+ B6.BoyJ BM from samples mobilized with G-CSF (2 times/d for 4 d as in Fig. 2B; n = 3), G-CSF + AMD3100 (5 mg/kg; n = 4), and AMD3100 (5 mg/kg; n = 3). Homing was assessed as in Materials and methods. (D, ii) Competitive repopulation of CD45.2+ BM cells recovered after homing shown in D, i. Results of chimerism are after 4 mo in 2° irradiated B6.BoyJ recipients. For A–D, significant differences compared with G-CSF: *P < 0.001; **P < 0.01; ***P < 0.05; all other values are P > 0.05. NA, data not depicted.

References

    1. Kondo, M., A.J. Wagers, M.G. Manz, S.S. Prohaska, D.C. Scherer, G.F. Beilhack, J.A. Shizuru, and I.L. Weissman. 2003. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21:759–806.
    1. Manz, M.G., K. Akashi, and I.L. Weissman. 2004. Biology of hematopoietic stem and progenitor cells. Thomas' Hematopoietic Cell Transplantation. 3rd ed. K.G. Blume, S.J. Forman, and F.R. Appelbaum, editors. Blackwell Publishing Ltd., Malden, MA. 69–95.
    1. Cooper, S., and H.E. Broxmeyer. 1996. Measurement of interleukin-3 and other hematopoietic growth factors, such as GM-CSF, G-CSF, M-CSF, erythropoietin and the potent co-stimulating cytokines steel factor and Flt-3 ligand. Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, and R. Coico, editors. John Wiley & Sons, Inc., NY. Supp. 18, 6.4.1–6.4.12.
    1. Wright, D.E., A.J. Wagers, A.P. Gulati, F.L. Johnson, and L.L. Weissman. 2001. Physiological migration of hematopoietic stem and progenitor cells. Science. 294:1933–1936.
    1. Abkowitz, J.L., A.E. Robinson, S. Kale, M.W. Long, and J. Chen. 2003. The mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood. 102:1249–1253.
    1. Broxmeyer, H.E., and F.O. Smith. 2004. Cord blood hematopoietic cell transplantation. Thomas' Hematopoietic Cell Transplantation. 3rd ed. K.G. Blume, S.J. Forman, and F.R. Appelbaum, editors. Blackwell Publishing Ltd., Malden, MA. 550–564.
    1. Ng-Cashin, J., and T. Shen. 2004. Mobilization of autologous peripheral blood hematopoietic cells for support of high-dose cancer therapy. Thomas' Hematopoietic Cell Transplantation. 3rd ed. K.G. Blume, S.J. Forman, and F.R. Appelbaum, editors. Blackwell Publishing, Ltd., Malden, MA. 576–587.
    1. Schmitz, N. 2004. Peripheral blood hematopoietic cells for allogeneic transplantation. Thomas' Hematopoietic Cell Transplantation. 3rd ed. K.G. Blume, S.J. Forman, and F.R. Appelbaum, editors. Blackwell Publishing, Ltd., Malden, MA. 588–598.
    1. Papayannopoulou, T. 2004. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood. 103:1580–1588.
    1. Roberts, A.W., E. DeLuca, C.G. Begley, R. Basser, A.P. Grigg, and D. Metcalf. 1995. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells. 13:512–516.
    1. Roberts, A.W., S. Foote, W.S. Alexander, C. Scott, L. Robb, and D. Metcalf. 1997. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood. 9:2736–2744.
    1. De Haan, G., A. Ausema, M. Wilkens, G. Molineux, and B. Dontje. 2000. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br. J. Haematol. 110:638–646.
    1. Croop, J.M., R. Cooper, C. Fernandez, V. Graves, S. Kreissman, H. Hanenberg, F.O. Smith, and D.A. Williams. 2001. Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood. 98:2917–2921.
    1. Hu, J., and C.E. Dunbar. 2002. Update on hematopoietic stem cell gene transfer using non-human primate models. Curr. Opin. Mol. Ther. 4:482–490.
    1. Aiuti, A., I.J. Webb, C. Bleul, T. Springer, and J.C. Gutierrez-Ramos. 1997. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185:111–120.
    1. Kim, C.H., and H.E. Broxmeyer. 1998. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor and the bone marrow environment. Blood. 91:100–110.
    1. Jo, D.-Y., S. Rafii, T. Hamada, and M.A.S. Moore. 2000. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J. Clin. Invest. 105:101–111.
    1. Wright, D.E., E.P. Bowman, A.J. Wagers, E.C. Butcher, and L.L. Weissman. 2002. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J. Exp. Med. 195:1145–1154.
    1. Peled, A., I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T. Byk, A. Nagler, H. Ben-Hur, A. Many, L. Shultz, O. Lider, R. Alon, D. Zipori, and T. Lapidot. 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283:845–848.
    1. Lapidot, T., and O. Kollet. 2002. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/β2mnull mice. Leukemia. 16:1992–2203.
    1. Christopherson, K.W., II, G. Hangoc, C. Mantel, and H.E. Broxmeyer. 2004. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 305:1000–1003.
    1. Broxmeyer, H.E., S. Cooper, L. Kohli, G. Hangoc, Y.H. Lee, C. Mantel, D.W. Clapp, and C.H. Kim. 2003. Transgenic expression of stromal cell derived factor-1/CXCL12 enhances myeloid progenitor cell survival/anti-apoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J. Immunol. 170:421–429.
    1. Broxmeyer, H.E., L. Kohli, C.H. Kim, Y. Lee, C. Mantel, S. Cooper, G. Hangoc, M. Shaheen, X. Li, and D.W. Clapp. 2003. Stromal cell derived factor-1/CXCL12 enhances survival/anti-apoptosis of hematopoietic stem and myeloid progenitor cells: direct effects mediated through CXCR4 and Gαi proteins. J. Leuk. Biol. 73:630–638.
    1. Shen, H., T. Cheng, I. Olszak, E. Garcia-Zepeda, Z. Lu, S. Hermann, R. Fallon, A.D. Luster, and D.T. Scadden. 2001. CXCR-4 desensitization is associated with tissue localization of hematopoietic progenitor cells. J. Immunol. 166:5027–5033.
    1. Hattori, K., B. Heissig, K. Tashiro, T. Honjo, M. Tateno, J.H. Shieh, N.R. Hackett, M.S. Quitoriano, R.G. Crystal, S. Rafii, and M.A. Moore. 2001. Plasma elevation of stromal cell-derived factor-1 induced mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 97:3354–3360.
    1. Sweeny, E.A., H. Lortat-Jacob, G.V. Priestley, B. Nakamoto, and T. Papayannopoulou. 2002. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood. 99:44–51.
    1. Petit, I., M. Szyper-Kravitz, A. Nagler, M. Lahav, A. Peled, L. Habler, T. Ponomaryov, R.S. Taichman, F. Arenzana-Seisdedos, N. Fujii, et al. 2002. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3:687–694.
    1. De Clercq, E. 2003. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2:581–587.
    1. Hatse, S., K. Princen, G. Bridger, E. De Clercq, and D. Schols. 2002. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527:255–262.
    1. Joo, E.K., H.E. Broxmeyer, H.J. Kwon, H.B. Kang, J.S. Kim, J.S. Lim, Y.K. Choe, I.S. Choe, P.K. Myung, and Y. Lee. 2004. Enhancement of cell survival by stromal cell–derived factor-1/CXCL12 involves activation of CREB and induction of Mcl-1 and c-Fos in factor-dependent human cell line MO7e. Stem Cells Dev. 13:563–570.
    1. Liles, W.C., H.E. Broxmeyer, E. Rodger, B. Wood, K. Hubel, S. Cooper, G. Hangoc, G. Bridger, G.W. Hensen, G. Calandra, and D.C. Daly. 2003. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 102:2728–2730.
    1. Hubel, K., W.C. Liles, H.E. Broxmeyer, E. Rodger, B. Wood, S. Cooper, G. Hangoc, R. MacFarland, G.J. Bridger, G.W. Henson, G. Calandra, and D.C. Dale. 2004. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Supportive Cancer Therapy. 1:165–172.
    1. Devine, S.M., N. Flomenberg, D.H. Vesole, J. Liesveld, D. Weisdorf, K. Badel, G. Calandra, and J.F. DiPersio. 2004. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22:1095–1102.
    1. Liles, W.C., E. Rodger, H.E. Broxmeyer, C. Dehner, K. Badel, G. Calandra, J. Christensen, B. Wood, T.H. Price, and D.C. Dale. 2004. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with G-CSF by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 45:295–300.
    1. Broxmeyer, H.E., S. Cooper, G. Hangoc, J.-L. Gao, and P.M. Murphy. 1999. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J. Exp. Med. 189:1987–1992.
    1. Harrison, D. 1980. Competitive repopulation: a new assay for long term stem cell functional capacity. Blood. 55:77–81.
    1. Haneline, L., H.E. Broxmeyer, S. Cooper, G. Hangoc, M. Carreau, M. Buchwald, and D.W. Clapp. 1998. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac −/− mice. Blood. 91:4092–4098.
    1. Dick, J.E., M. Bhatia, O. Gan, U. Kapp, and J.C. Wang. 1997. Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells. 15:199–203.
    1. Bodine, D. 2004. Animal models for the engraftment and differentiation of human hematopoietic stem and progenitor cells. Cord Blood: Biology, Immunology, Banking, and Clinical Transplantation. H.E. Broxmeyer, editor. American Association of Blood Banking, Bethesda, MD. 47–64.
    1. Orschell-Traycoff, C.M., K. Hiatt, R.N. Dagher, S. Rice, M.C. Yoder, and E.F. Srour. 2000. Homing and engraftment potential of Sca-1(+)lin(−) cells fractionated on the basis of adhesion molecule expression and position in cell cycle. Blood. 96:1380–1387.
    1. Thomas, E.D. 2004. A history of bone marrow transplantation. Thomas' Hematopoietic Cell Transplantation. 3rd ed. K.G. Blume, S.J. Forman, and F.R. Appelbaum, editors. Blackwell Publishing Ltd., Malden, MA. 3–8.
    1. Grigg, A.P., A.W. Roberts, H. Raunow, S. Houghton, J.E. Layton, A.W. Boyd, K.M. McGrath, and D. Maher. 1995. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 86:4437–4445.
    1. Anderlini, P., D. Przepiorka, C. Seong, T.L. Smith, Y.O. Huh, J. Lauppe, R. Champlin, and M. Korbling. 1997. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion. 37:507–512.
    1. Holm, M. 1998. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J. Hematol. 7:111–113.
    1. de la Rubia, J., C. Arbona, F. de Arriba, C. del Canizo, S. Brunet, C. Zamora, M.A. Diaz, J. Bargay, J. Petit, J. de la Serna, et al. 2002. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion. 42:4–9.
    1. Bhatia, M., J.C. Wang, U. Kapp, D. Bonnet, and J.E. Dick. 1997. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. USA. 94:5320–5325.
    1. Chen, M., D.J. Tomkins, W. Auerbach, C. McKerlie, H. Youssoufian, L. Liu, O. Gan, M. Carreau, A. Auerbach, T. Groves, et al. 1996. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconia anemia. Nat. Genet. 12:448–451.
    1. Wilpshaar, J., J.H. Falkenburg, X. Tong, W.A. Noort, R. Breese, D. Heilman, H. Kanhai, C.M. Orschell-Traycoff, and E.F. Srour. 2000. Similar repopulating capacity of mitotically active and resting umbilical cord blood CD34+ cells in NOD/SCID mice. Blood. 96:2100–2107.
    1. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614–1619.
    1. Plett, P., S. Frankovitz, F. Wolber, R. Abonour, and C. Orschell-Traycoff. 2002. Treatment of circulating CD34+ cells with SDF-1α or anti-CXCR4 antibody enhances migration and NOD/SCID repopulating potential. Exp. Hematol. 30:1061–1069.
    1. Plett, P.A., S.M. Frankovitz, and C.M. Orschell-Traycoff. 2002. In vivo trafficking, cell cycle activity, and engraftment potential of phenotypically defined primitive hematopoietic cells after transplantation into irradiated or nonirradiated recipients. Blood. 100:3545–3552.
    1. Plett, P.A., S.M. Frankovitz, and C.M. Orschell. 2003. Distribution of marrow repopulating cells between bone marrow and spleen early after transplantation. Blood. 102:2285–2291.
    1. Boggs, D. 1984. The total marrow mass of the mouse: a simplified method of measurement. Am. J. Hematol 16:277–286.
    1. Jetmore, A., P.A. Plett, X. Tong, F.M. Wolber, R. Breese, R. Abonour, C.M. Orschell-Traycoff, and E.F. Srour. 2002. Homing efficiency, cell cycle kinetics and survival of quiescent and cycling human CD34+ cells transplanted into conditioned NOD/SCID mice. Blood. 99:1585–1593.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe